MFG
VRTX icon

Merit Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Merit Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.07M Buy
12,218
+1,883
+18% +$835K 0.04% 378
2026
Q1 		$4.62M Buy
10,335
+1,368
+15% +$638K 0.03% 412
2025
Q4 		$4.07M Buy
8,967
+2,880
+47% +$1.24M 0.03% 413
2025
Q3 		$2.38M Sell
6,087
-173
-3% -$72.3K 0.02% 506
2025
Q2 		$2.79M Buy
6,260
+833
+15% +$384K 0.03% 422
2025
Q1 		$2.63M Buy
5,427
+496
+10% +$231K 0.04% 354
2024
Q4 		$1.99M Buy
4,931
+2,155
+78% +$999K 0.04% 356
2024
Q3 		$1.29M Sell
2,776
-1,001
-27% -$481K 0.03% 356
2024
Q2 		$1.77M Buy
3,777
+342
+10% +$148K 0.04% 292
2024
Q1 		$1.38M Buy
3,435
+1,477
+75% +$624K 0.03% 333
2023
Q4 		$797K Sell
1,958
-1,698
-46% -$627K 0.02% 370
2023
Q3 		$1.27M Sell
3,656
-275
-7% -$96.2K 0.04% 283
2023
Q2 		$1.38M Buy
3,931
+2,297
+141% +$774K 0.04% 280
2023
Q1 		$515K Buy
+1,634
New +$490K 0.02% 394

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

Merit Financial Group's VRTX Position: Q2 2026 in Review

Merit Financial Group increased its Vertex Pharmaceuticals (VRTX) stake by 18% in Q2 2026, buying an estimated $835K and bringing the position to 12,218 shares worth $6.07M. The position accounts for 0.04% of the portfolio, ranked #378.

Merit Financial Group first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. 307 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Merit Financial Group held 12,218 shares of Vertex Pharmaceuticals worth $6.07M as of Q2 2026.
  • Merit Financial Group bought 1,883 Vertex Pharmaceuticals shares in Q2 2026, an estimated $835K.
  • Vertex Pharmaceuticals made up 0.04% of Merit Financial Group's portfolio in Q2 2026, its #378 holding.
  • Merit Financial Group first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 307 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.